Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accounts Payables (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Accounts Payables readings, the most recent being $4.0 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 54.88% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 54.88% increase, with the full-year FY2025 number at $4.0 million, up 54.88% from a year prior.
  • Accounts Payables hit $4.0 million in Q4 2025 for Aligos Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.8 million in Q2 2024 to a low of $1.6 million in Q2 2021.
  • Median Accounts Payables over the past 5 years was $2.9 million (2022), compared with a mean of $3.4 million.
  • Biggest five-year swings in Accounts Payables: crashed 46.87% in 2023 and later skyrocketed 110.4% in 2024.
  • Aligos Therapeutics' Accounts Payables stood at $3.0 million in 2021, then surged by 57.11% to $4.7 million in 2022, then crashed by 46.87% to $2.5 million in 2023, then increased by 2.15% to $2.6 million in 2024, then surged by 54.88% to $4.0 million in 2025.
  • The last three reported values for Accounts Payables were $4.0 million (Q4 2025), $4.7 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.